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Abstract
Background: People with bipolar disorder often show difficulties with cognitive functioning, and though these
difficulties are identified as important targets for intervention, few treatment options are available. Preliminary
evidence suggests that cognitive remediation therapy (a psychological treatment proven beneficial for people
diagnosed as having schizophrenia) is helpful for people with bipolar disorders. We are conducting a pilot trial to
determine whether individual, computerised, cognitive remediation therapy (CRT) for people with bipolar disorder
1) increases cognitive function; 2) improves global functioning, goal attainment and mood symptoms; 3) is
acceptable and feasible for participants; and 4) can be addressed in a comprehensive, larger, randomised,
controlled trial.
Methods/design: The study is designed as a two-arm, randomised, controlled trial comparing cognitive
remediation therapy with treatment-as-usual (TAU) for euthymic bipolar patients. Participants are eligible to take
part if aged between 18 and 65 with a diagnosis of bipolar disorder (type I) and currently in euthymic state, and no
neurological, substance or personality disorder diagnoses. Sixty participants will be recruited (mainly through
secondary and tertiary care) and will be block-randomised to receive either treatment-as-usual alone or in addition
to a 12-week course of cognitive remediation therapy totalling 20–40 therapy hours. The intervention will comprise
regular sessions with a therapist and computer-based training. Research assessments will take place before and
after the intervention period and at a 12-week follow-up, and will include evaluation of neuropsychological,
symptom-related, demographic and social factors, as well as collecting qualitative data regarding CRT expectations
and satisfaction. Intention-to-treat analyses will examine the efficacy of cognitive remediation therapy primarily on
cognition and additionally on functioning, quality of life and mood symptoms. Furthermore, we will examine the
acceptability of CRT and undertake a preliminary health economics analysis to ascertain the cost of delivering the
intervention.
Discussion: The results of this trial will provide valuable information about whether cognitive remediation therapy
may be beneficial for people diagnosed with bipolar disorder in a euthymic state.
Trial Registration: ISRCTN registry, ISRCTN32290525. Registered on 2 March 2016
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Background
Bipolar disorder is one the most disabling health-related
conditions, contributing at least 2 % to the total disability
adjusted life-years of non-communicable diseases world-
wide in 2005 [1]. It typically first occurs at the beginning
of adult life, when life-long relationship and occupational
trajectories are established, potentially causing serious and
long-lasting social and functional impairment. The cost to
society is also considerable, both in terms of the lost prod-
uctivity of individuals and in the direct costs related to
provision of health care [2]. The provision of secondary
preventative treatment would reduce the personal burden
of the illness, and fewer future hospitalisations would pro-
vide a significant cost saving to health services. While re-
search indicates that overall individuals with psychiatric
diagnoses show better recovery when pharmacological
and psychological treatments are provided concomitantly
[3], further research is required to develop and investigate
useful psychological interventions that are cost-effective
and could be provided routinely in health services for bi-
polar disorder.
One potential target for therapy is cognition: bipolar
disorder is associated with widespread cognitive deficits
(perhaps most notably in executive function) that can
persist even during periods of recovery and are associ-
ated with poorer levels of functioning [4]. Findings are
consistent with a pattern of cognitive deterioration as
the number and severity of the episodes increase, and
cognitive impairment is a factor that may predict in-
creased recurrence of episodes [5]. Therefore, an im-
provement in cognition might enhance not only short-
term function and quality of life (possibly facilitated by
meta-cognition) but potentially also the overall course of
illness. This pattern of findings in bipolar disorder is
similar to schizophrenia, for which a new psychological
treatment targeting cognition has shown promising re-
sults: cognitive remediation therapy (CRT). CRT aims to
target fundamental cognitive processes, including atten-
tion and memory, but also executive functioning which
requires the combination of basic cognitions and meta-
cognitive skills to aid the transfer into everyday practice
of improved cognition to enhance quality of life [6]. In
people with diagnoses of schizophrenia, CRT has dem-
onstrated improvements in the realms of cognitive, work
and social functioning, quality of life and severity of
symptoms experienced [7–9].
In mood disorders, a meta-analysis of CRT trials in-
cluding patients with various affective disorders has
demonstrated a beneficial effect of CRT on cognitive
performance [10], although no trials included a purely
bipolar sample. More recently, a pilot trial using a func-
tional targeted therapy that included cognitive remedi-
ation identified benefits to the quality of life for people
with bipolar disorder [11, 12].
CIRCuiTs is a partly computerised CRT interven-
tion, developed from a paper-and-pencil version of
the therapy and building upon the existing CRT
literature. Using the program, clients are taught
cognitive strategies to help them improve their think-
ing skills (e.g. memory, concentration and planning),
and the therapist facilitates reflection around how
these strategies can be applied to meet their everyday
goals (e.g. shopping, looking for work) including the
application of metacognitive strategies. CIRCuiTs has
demonstrated high levels of acceptability, usability
and comprehensibility to participants, with high
levels of satisfaction with the experience reported
[13].
We anticipate that this intervention may facilitate op-
timisation of the management of bipolar disorder
through improvements in cognitive functioning in com-
bination with the development of metacognitive skills
and elements focusing on transfer to everyday life. As
such, a pilot randomised trial is being conducted to in-
vestigate whether a cost-effective but intensive cognitive
remediation therapy (CIRCuiTs) is a viable treatment for
bipolar disorder.
Objectives
The overarching aim of this trial is to determine
whether CRT can serve as a new, evidence-based
treatment for bipolar disorder. In order to achieve
this, the following research questions are being inves-
tigated as primary objectives, as they are all funda-
mental pre-requisites of future examination of CRT
for bipolar disorder:
1) Does CRT improve overall cognition (specifically
learning, verbal and working memory, intellectual
functioning, attention and executive functions)?
2) Does CRT provide further, specific benefits to
participants (i.e. everyday functioning, mood
symptoms and achievement of self-defined goals)?
3) Do people with bipolar disorder feel that CRT is
beneficial and acceptable?
4) Can sufficient patients be recruited to conduct a
larger, more comprehensive RCT?
Potential moderators or mediators for the benefits
of CRT will additionally be explored on a secondary
basis.
Methods/design
The study is being conducted in accordance with CON-
SORT and SPIRIT guidelines. The CRiB study was ap-
proved by City Road & Hampstead NHS Research Ethics
Committee on 16/10/2015 (reference 15/LO/1557).
Strawbridge et al. Trials  (2016) 17:371 Page 2 of 9
Trial design
See Fig. 1 for the study flow chart. This is a pilot and
feasibility randomised controlled trial, which com-
prises a 12-week intervention period followed by a
12-week follow-up period. Randomisation will ensure
a 1:1 allocation ratio of participants to either Cogni-
tive Remediation Therapy (CRT) in addition to
Treatment-As-Usual (n = 30) or TAU alone (n = 30)
for the intervention period. Measures will assess the
outcomes before (baseline; week 0), after (week 13)
the intervention period, and after the follow-up
period (week 25). Two self-report symptom measures
of depression and mania will be completed by all
participants at weeks 1, 4, 8 and 12 during the inter-
vention period to monitor wellbeing.
Setting
The study will take place in one of two clinical aca-
demic settings in South London: The Clinical Re-
search Facility (CRF), King’s College Hospital, or the
OPTIMA mood disorders clinic, Lambeth Hospital,
both South London and Maudsley NHS Foundation
Trust (SLaM; London, UK). Both are quiet and pri-
vate spaces that the participant can select from at
their convenience but for each participant will be
consistent between all assessment sessions.
Fig. 1 CONSORT flow diagram. The flow chart depicts participant progression through the study from initial enrolment through allocation,
follow-up and finally analyses of their data stages
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Participants
Thirty participants will be assigned to the intervention
arm (CRT with TAU) and 30 to the control arm (TAU
alone); this sample size is recommended for pilot trials
[14] to estimate efficacy by corroborating effect sizes for
cognitive and functional outcomes. We anticipate recruit-
ing approximately half of the sample from secondary/ter-
tiary care and half from the community (approximately 15
from each recruitment strand per group). Community re-
cruitment will comprise public advertisements using
methods that have previously been successful [15]. Partici-
pants will be recruited if fully informed and willing to par-
ticipate and if they meet the following inclusion criteria:
aged 18–65, have a confirmed DSM-V diagnosis of bipolar
I disorder (using the Mini International Neuropsychiatric
Interview [16]), and be in a euthymic state at two time
points 1 week apart, defined by scores of < 8 on the
Hamilton Rating Scale for Depression and Young Mania
Rating Scale (standardised cut-off scores for euthymia [17]
on both occasions. No constraints exist based on sex or
prior treatment, but fluency in English and the ability to
use a computer are required (assessed verbally). Further-
more, we will exclude potential participants if they have
evidence of a substantial neurological, neurodegenerative,
substance-use or current diagnosis of personality disorder
(assessed using standardised measures). Both women who
are pre- and post-menopausal will be included; meno-
pausal status and current phase of menstrual cycle at each
assessment time point will be reported verbally and re-
corded. This will also be controlled for in analyses due to
reliable findings of cognitive variations across the men-
strual cycle [18].
Participants will be selected from services within
South London and Maudsley NHS Trust (the national
Affective Disorders Service and the OPTIMA Mood
Disorders Programme), by identification of potentially
eligible individuals through the Consent for Contact
(C4C) SLaM initiative [19], which allows approved re-
searchers access to a computerised retrieval system to
rapidly screen limited, relevant case notes of consenting
service users and by community advertisements and a
research webpage.
Procedures
Pre-inclusion
Following provision of study information and verbal
consent for screening, the initial screening interview
(Screen A) will involve questions about demographics
(age, received diagnoses), a diagnostic assessment and
researcher-rated and self-report measures of depressive
and manic symptoms. If not excluded so far, a second
screening (Screen B) will take place 1 week later to val-
idate stable asymptomatic state. Prior to inclusion, bipo-
lar disorder diagnoses will be validated by a practising
psychiatrist from the study team, by verbally discussing
the scoring of the MINI assessment with the assessor
and requesting further information if required).
Randomisation
Following fully informed written consent, participants
will be randomised to one of the two treatment arms
(TAU or TAU + CRT). Randomisation is facilitated by
the King’s College Clinical Trials Unit independent web-
based system [20], holding the details needed for ran-
domisation (treatment program, date of birth, and
unique identity number). Trial participants will be ran-
domised between the two parallel groups in a 1:1 alloca-
tion (30 participants per treatment group). A stratified
block randomisation will allocate participants to treat-
ment groups, with an equal number of participants in
each stratification group (intensive-secondary or tertiary
care; standard secondary care) using an initial random
allocation sequence (n cases). All randomisation details
will be locked following treatment allocation. The lead
researcher (RS) will not be blinded to treatment alloca-
tion but the researcher conducting research assessments
and trial statistician will be blind.
Treatment as usual
All 60 participants will continue receiving treatment as
usual; the study does not affect concomitant interventions
in any way. However, we will measure service use, so all
current treatments for all patients are recorded. TAU is
not expected to affect the outcome measures or systemat-
ically differ between participants, but intensity of current
treatments is stratified between intervention arms.
CRT intervention
CRT will be delivered over the course of a 12-week
period, flexibly utilising a combination of formats (i.e.,
face-to-face, telephone, drop-in sessions and individual
practice), amounting to approximately 30–40 hours of
CRT. Face-to-face sessions (up to 1 hour long) will be
held at least once per week, but participants will be en-
couraged to attend up to three sessions per week if feas-
ible; an alternative arrangement of twice-weekly
telephone sessions (in addition to one face-to-face ses-
sion) will be offered. Additionally, all individuals will be
provided unlimited access to use the program in their
own time, for practising independently as they wish,
with an option to receive reminder text-messages that
can be sent to participants up to twice per week. This
intervention aims are tailored to individual needs, using
a format beneficial for themselves specifically. Where
possible, and only with the participants’ agreement at
each session, therapy meetings will be video-recorded or
auditory-only recorded; this will assist with ensuring
therapist fidelity and optimising the intervention for
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future use. CRT is considered a safe therapy, unlikely to
have an impact on risky behaviours, and the participants
should not be experiencing symptoms during the trial.
Though we perceive this not to be a high-risk study, the
participants are considered a vulnerable population, and
a small risk exists that they will not engage positively
with, or more importantly, will have a negative emo-
tional reaction to the intervention (e.g. frustration may
be experienced upon failure to complete a particular
task). Despite existing evidence indicating that people
find CRT helpful and acceptable, we will ensure that
CRT therapists are comprehensively trained and pre-
pared to manage such situations (using supportive and
solution-focused approaches). Effort will be put into
avoiding such circumstances by following standardised
protocols which researchers will be trained in for ad-
verse situations. We emphasise that the intervention is
delivered using positive methods and has reliably elicited
positive feedback from patients during previous trials.
CRT therapists will be psychologists (to post-graduate-
level study at minimum), who have received specific
training from experts in the intervention, on CRT and
the CIRCuiTs program specifically. They receive ongoing
supervision from experienced CRT practitioners. Pro-
cesses are in place to deal with any safety issues that in-
clude ongoing participant monitoring throughout the
intervention period; completion of self-report symptom
measures on a monthly basis, and prompts from a re-
searcher to safeguard completion and scoring. In any in-
stances where scores exceed the standardised cut-offs
for depression or mania, individuals will receive a call
from a researcher (or a therapist if concerns persist). If
necessary, a therapist or clinician and participants will
discuss and agree whether there is a need for trial with-
drawal. Additional concerns about safety and wellbeing
will be conveyed to the participant’s contact healthcare
professional. A copy of the consent form alongside a let-
ter of notification and information sheet is sent to nomi-
nated healthcare professional for all participants. Trial
participation (and whether CRT is being undertaken) is
to be recorded on patient’s health records as the trial af-
fects clinical care and may be important for treatment-
related decisions. A data management plan (in adher-
ence with the Research Governance Framework) has
been developed to ensure protocols for quality assured
monitoring and safety are maintained during the trial.
Data monitoring support is also accessible through the
trial steering committee and trial specific working
manual.
Measures
See Table 1 for a summary of study measures at each
time point.
Primary outcomes
The putative primary outcome measure is the digit
symbol coding test from the Wechsler Adult Intelligence
Scales 4th Edition (WAIS [21], akin to the digit symbol-
substitution test (DSST)), measured at baseline (week 0),
at post-intervention (week 13) and follow-up assess-
ments (week 25). This was selected as the measure
which has been identified widely as sensitive to change
and representative of cognition, measuring domains in-
cluding but not limited to visuospatial processing, atten-
tion control and switching, associative learning,
executive control and short-term memory [22, 23].
Also measured at Weeks 0, 13 and 25, the remaining cog-
nitive outcomes assess: current IQ performance, measured
in the WASI-II test (two-subtest version of the Wechsler
Abbreviated Scale of Intelligence 2nd Edition [24]; verbal
memory assessed in the verbal paired associates I and II
tasks from the Wechsler Memory Scales 4th Edition [25]
(WMS); digital memory and reasoning measured in the
digit span and symbol search tasks from the WAIS
(Wechsler Adult Intelligence Scales 4th Edition [21]); verbal
fluency assessed in the Delis-Kaplan Executive Function
System (DKEFS [26]); executive function, from the Hotel
test of planning and multi-tasking abilities [27] revised ver-
sion (personal communication JF, Dr Tom Manly). A com-
posite score (comprising all of the above cognitive
outcomes) of cognition will also be calculated for feasibility
and the acceptability of the intervention (measured using
numbers completing CRT and number of hours under-
taken) is also a primary outcome, assessing objective 3. Per-
ceived cognitive impairments are evaluated using the
Perceived Deficits Questionnaire (PDQ [28]) at weeks 0, 13
and 25.
In addition, at the three main assessment time points
(weeks 0, 13 and 25), the additional outcomes are mea-
sured: The Functional Assessment Short Test (FAST
[29]) calculates everyday functioning; the Goal Attain-
ment Scale (GAS), a personalised measure of goal attain-
ment [30]; and experiences of alexithymia (assessed
using the Toronto Alexithymia Scale; TAS-20 [31].
Researcher-rated severity of depressive (Hamilton Rating
Scale for Depression; HAMD [32]) and manic (Young
Mania Rating Scale; YMRS [33]) symptoms are con-
ducted to establish euthymia at screening (both A and
B) and at the three assessment time points (weeks 0, 13
and 25). Subjective symptom assessments are addition-
ally conducted at all study time points (0, 1, 4, 8, 12, 13
and 25 weeks) using the Inventory of Depressive Symp-
toms (IDS [34]) and Altman Self-Rated Mania (ASRM
[35]) scales.
Before (week 0) and after the intervention (week
13), qualitative questionnaires will measure the feasi-
bility and satisfaction with Cognitive Remediation
Therapy [36].
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Extent of current health service-usage and health-
related quality of life are assessed using an adapted ver-
sion of the Client Service Receipt Inventory (CSRI [37])
and the EQ-5D measure [38]) respectively, at the second
screening session (Screen B) and then after treatment
(week 13) and follow-up (week 25). These measures are
used also to calculate the estimated cost of providing
CRT (alongside data recorded from CRT, e.g. number of
therapist hours).
Attendance to face-to-face and telephone sessions, as
well as amount of time spent individually practising
CRT will be monitored; the CIRCuiTs program records
extensive data regarding usage automatically.
Secondary outcomes
Approximate premorbid IQ is measured using the Test
of Premorbid Function (TOPF [39]) at baseline (week 0).
Also at the baseline assessment only (week 0), anxiety
levels are measured using the Hamilton Anxiety rating
scale (HAM-A [40]), history of childhood trauma using
the Childhood Trauma Questionnaire (CTQ [41]), per-
sonality disorder traits (using the SCID-BPD; Structured
Clinical Interview for DSM-IV disorders, borderline
scale [42] and SAPAS; the Standardised Assessment of
Personality–Abbreviated Scale [43]) and general person-
ality traits (assessed using the TDSI; The Trait Self-
Description Inventory [44]).
Other measures
At Screen A, the diagnostic assessment includes the
MINI (Mini International Neuropsychiatric Interview
[16] structured assessment for common mental disor-
ders; the bipolar disorder, substance use, and personality
disorder sections to be completed first to determine eli-
gibility, and the MoCA (Montreal Cognitive Assessment
[45]) which screens for symptoms of dementia (for
Table 1 Study measures and time points
Concept Measure Screen
A
Screen
B
Week
0
Week
1
Week
4
Week
8
Week
12
Week
13
Week
25
Cognitive Wechsler Adult Intelligence Scale (WAIS) X X X
Wechsler Abbreviated Scale of Intelligence (WASI) X X X
Wechsler Memory Scale (WMS) X X X
Delis-Kaplan Executive Function System (DKEFS) X X X
Hotel Test X X X
Test of Premorbid Functioning (TOPF) X
Perceived Deficits Questionnaire (PDQ) X X X
Functional Functional Assessment Short Test (FAST) X X X
Goal-attainment Scale (GAS) X X X
Mood-
related
Toronto Alexithymia Scale (TAS-20) X X X
Hamilton Rating Scale for Depression (HAMD) X X X X X
Young Mania Rating Scale (YMRS) X X X X X
Inventory of Depressive Symptomatology (IDS) X X X X X X X X X
Altman Self-rating Mania scale (ASRM) X X X X X X X X X
Hamilton Anxiety Rating Scale (HAM-A) X
Psycho-
social
Childhood Trauma Questionnaire (CTQ) X
Structured Clinical Interview for DSM (axisII), BPD scale
(SCID-BPD)
X
Standardised Assessment of Personality – Abbreviated
Scale (SAPAS)
X
Trait Self-description Inventory (TSDI) of personality X
Other Qualitative questions X X
Client Service Receipt Inventory (CSRI) X X X
WHO quality of life measure (EQ-5D) X X X
Mini Neuropsychiatric Interview (MINI) X
Montreal Cognitive Assessment; (MoCA) X
Demographic information X X X
Week 0 = baseline assessment, Week 13 = post-intervention assessment, Week 25 = follow-up assessment
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inclusion total score must be below 26). Demographic
information collected (at Screen A and week 0) includes
data regarding age, employment, physical health and re-
cent life events. All regular medications of each partici-
pant will be recorded and any changes in medication
will be noted at the post-intervention and 12-week
follow-up sessions. We will carefully monitor adverse
events and patient safety at every time point (Weeks 0,
1, 4, 8, 12, 13 and 25), and any concerns in this regard
will be promptly taken to the Lead PI and Steering
Committee.
Statistics
Analyses will be carried out by the trial statistician. The
main purpose of the statistical analyses is to estimate
trial and intervention feasibility parameters. Thus, we
will use largely descriptive statistics with inferential sta-
tistics used to generate respective confidence intervals
and effect sizes. The analyses can be split into three
aims: 1) estimation of parameters that evaluate trial
feasibility (recruitment rates, randomisation rates and at-
trition rates), to meet objective 4; 2) estimation of pa-
rameters that measure intervention feasibility
(adherence, treatment fidelity and patient satisfaction) in
accordance with objective 3; and 3) estimates of inter-
vention effect sizes (mean differences and standard devi-
ations) in terms of potential primary outcomes of future
trials or variables that are targeted by the therapy (puta-
tive mediators of future treatment effects), addressing
objectives 1 and 2. All statistical analyses will adopt the
intention-to-treat (ITT) principle and will be conducted
after data collection has been completed.
Trial feasibility (objective 4) and intervention feasibility
(objective 3) parameters
The analysis will firstly consist of descriptive statistics to
assess the rate of consent of eligible patients, the accept-
ability of CRT to the patient population, treatment fidel-
ity, deviations from study protocol and study retention.
Participant demographic and clinical characteristics will
also be summarised at baseline. Patterns of missing data
or nonattendance will be described for the outcome at
measurement time-points and according to therapy ses-
sion, along with reasons for drop-out. As appropriate,
the statistics derived will be means and standard devia-
tions or medians, minimum values, maximum values
and interquartile range for continuous measures and
proportions for ordinal or multinomial categorical mea-
sures and binary coded measures.
Estimates for effect sizes for CRT versus TAU (objectives 1
and 2)
To assess improvement in cognitive and functioning do-
mains, estimates of treatment effect sizes will be
obtained using linear mixed models. These analyses will
provide the treatment effect estimate on each outcome
at 13 and 25 weeks. The linear mixed model will contain
post-treatment measures of the outcome at the two
follow-up time points, i.e. 13 and 25 weeks as the
dependent variables with fixed effects of trial arm, base-
line measure of outcome, time and a time point by trial
arm interaction to allow treatment effects to differ at 13
and 25 weeks. Baseline measures of the primary out-
comes are included as they are potential predictors of
future outcome and thus should help us to gain preci-
sion for effect estimates of interest. A random effect for
participant will be entered in to the model to account
for correlations between the two repeated measures per
participant. In addition, to account for the correlation of
level-1 residuals across time, an exchangeable residual
covariance structure will be included in the model. We
will also consider changes in cognitive variables as medi-
ators of improvements in functional outcomes (FAST).
The aim here is to derive an effect size and inferential
statistics will not be reported.
With respect to missing data, linear mixed models will
be estimated using maximum likelihood (ML). Such an
approach provides valid inferences under the assumption
that the missing data mechanism is ignorable (or missing
at random, MAR). Here, this means that explanatory
variables included in the model can predict missingness
as can earlier observed values of the outcome. We will
include baseline predictors of drop-out as explanatory
variables in the linear mixed model to make the MAR
assumption more realistic. However, given the small
dataset the number of explanatory variables to be in-
cluded will be necessarily small. Finally, Sensitivity ana-
lysis will be used to assess the robustness of the
conclusions to missing outcome data in which missing
values will be imputed according to various plausible
scenarios, e.g. participants with missing data showing no
improvement in cognitive outcomes.
Economic analyses
Service use measured with the Client Service Receipt In-
ventory will be combined with appropriate unit costs
[46]). The costs of the intervention, which will be based
on the resources required to deliver it (staff time and
overheads) and activity levels, will be added to these.
The EQ5D will be used to derive quality-adjusted life
years. These will be combined with the costs and com-
parisons made between the two groups. Uncertainty will
be addressed using cost-effectiveness planes derived
though bootstrapped resamples.
Discussion
CRT has the potential to increase cognitive function and
for improvements to translate to quality of everyday life
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and social and occupational functioning, as well as pos-
sibly to prevent the onset of mood symptoms. Our find-
ings should indicate whether a partly computerised, 12-
week course of cognitive remediation therapy can im-
prove cognition above treatment-as-usual.
Strengths
This study has been designed and is being conducted in
compliance with the principles of the Declaration of
Helsinki (1996), the principles of Good Clinical Practice
(GCP) and in accordance with all applicable regulatory
requirements including but not limited to the Research
Governance Framework and the Mental Capacity Act
(2005). These actions will maximise validity, participant
safety and scientific integrity as well as reduce bias. Add-
itionally during the planning stages we sought review of
the scientific quality of the study from a service user
panel (NIHR/MHRN’s FAST-R - Feasibility and Support
to Timely recruitment for Research - service) and infor-
mally by experienced academics and clinicians prior to
two stringent peer review processes for funding applica-
tion. The study was judged to be well-designed by a
strong team, and to be worthwhile in terms of putative
future implications. Trial Steering Committee monitor-
ing (which includes all study investigators, individuals
independent from the study team and service user repre-
sentatives), regular and experienced supervision for ther-
apists, and ongoing support and training for those
undertaking research assessments will ensure that qual-
ity is maximally maintained throughout the trial.
Limitations
Participants will be recruited via a number of routes,
and although this may increase the representativeness of
people with bipolar type I disorder, it may also increase
heterogeneity of our findings. The flexibility of the CRT
intervention (in terms of different modes of provision
and aspects focused on) may also increase heterogeneity.
Due to participant burden and resources, we are not able
to account for all potential confounders. In addition, as
we are not excluding participants based on cognitive
deficits, it is possible that some of our participants might
have high functioning and therefore not show improve-
ments with CRT (something important to be addressed
in future studies). The sample size for this pilot trial is
relatively small to detect differences of the domains be-
ing measured and provides a comparison of CRT with
treatment as usual care alone. The results will inform a
more comprehensive RCT comparing a CRT interven-
tion with an active placebo condition, to establish the ef-
fects of CRT for a group of people diagnosed with
bipolar disorder controlling for non-therapeutic but po-
tentially important factors (e.g. cognitive task-specific
improvements and time engagements).
This publication of our protocol aims to maximise re-
producibility and transparency of this pilot trial, which is
investigating the effects of CRT for people with bipolar
disorder; our findings will indicate whether this access-
ible program provides benefits to this population over
treatment-as-usual, which would represent a vital ad-
vance in psychological care for asymptomatic bipolar
disorder.
Trial status
The trial is ongoing. Recruitment commenced in Febru-
ary 2016.
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